Foghorn Therapeutics (FHTX) Return on Capital Employed (2020 - 2026)
Foghorn Therapeutics (FHTX) recorded quarterly Return on Capital Employed of 58.36% in Q1 2026, up 4.21% quarter-over-quarter from 60.93% in Q4 2025, and down 967.0% on a YoY basis from 6.73% in Q1 2025.
Foghorn Therapeutics (FHTX) Return on Capital Employed (2020 - 2026) Analysis & Trends
Foghorn Therapeutics' Return on Capital Employed history runs 7 years deep, the most recent figure standing at 58.36% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 967.0% year-over-year to 58.36%; the TTM figure through Mar 2026 stood at 58.36% (down 967.0% YoY), while the FY2025 annual figure was 47.65%, down 54.0% from the prior year.
- Return on Capital Employed was 58.36% for Q1 2026 at Foghorn Therapeutics, up from 60.93% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 23.13% in Q1 2022 to a low of 66.29% in Q3 2025.
- Historically, Return on Capital Employed has averaged 43.4% across 5 years, with a median of 41.89% in 2023.
- The sharpest annual moves came in 2022 and 2025: Return on Capital Employed surged 2344 bps in 2022, then sank 2649 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 32.16% in 2022, then sank by 39 bps to 44.73% in 2023, then declined by 0 bps to 44.8% in 2024, then tumbled by 36 bps to 60.93% in 2025, then rose by 4 bps to 58.36% in 2026.
- The last three Return on Capital Employed figures came in at 58.36% (Q1 2026), 60.93% (Q4 2025), and 66.29% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Foghorn Therapeutics | 282.33 Mn | 193.42 Mn | - | -58.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -58.36% |
| Dec 31, 2025 | -60.93% |
| Sep 30, 2025 | -66.29% |
| Jun 30, 2025 | -55.79% |
| Mar 31, 2025 | -48.69% |
| Dec 31, 2024 | -44.80% |
| Sep 30, 2024 | -39.80% |
| Jun 30, 2024 | -40.41% |
| Mar 31, 2024 | -47.06% |
| Dec 31, 2023 | -44.73% |
| Sep 30, 2023 | -41.65% |
| Jun 30, 2023 | -41.89% |
| Mar 31, 2023 | -36.82% |
| Dec 31, 2022 | -32.16% |
| Sep 30, 2022 | -29.04% |
| Jun 30, 2022 | -26.22% |
| Mar 31, 2022 | -23.13% |
| Dec 31, 2021 | -33.11% |
| Sep 30, 2021 | -52.49% |
| Jun 30, 2021 | -42.24% |